Search Results - "Verhaegh, W."

TTLL12 has a potential oncogenic activity, suppression of ligation of nitrotyrosine to the C-terminus of detyrosinated α-tubulin, that can be overcome by molecules identified by screening a compound library by Deshpande, Amit, Brants, Jan, Wasylyk, Christine, van Hooij, Onno, Verhaegh, Gerald W, Maas, Peter, Schalken, Jack A, Wasylyk, Bohdan

“…Tubulin tyrosine ligase 12 (TTLL12) is a promising target for therapeutic intervention since it has been implicated in tumour progression, the innate immune…”
Get full text

Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis by Luna Velez, Maria V., Verhaegh, Gerald W., Smit, Frank, Sedelaar, J. P. Michiel, Schalken, Jack A.

“…One of the mechanisms by which advanced prostate cancer develops resistance to androgen deprivation therapy is the elevated expression of C-terminally…”
Get full text

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer by Groen, Levi, Kloots, Iris, Englert, David, Seto, Kelly, Estafanos, Lana, Smith, Paul, Verhaegh, Gerald W, Mehra, Niven, Schalken, Jack A

“…The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker is broadly recognized. The earliest methods for enriching CTCs…”
Get full text

Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer by HESSELS, Daphne, SMIT, Frank P, VERHAEGH, Gerald W, WITJES, J. Alfred, CORNET, Erik B, SCHALKEN, Jack A

“…Purpose: Early detection of prostate cancer can increase the curative success rate for prostate cancer. We studied the diagnostic usefulness of TMPRSS2-ERG…”
Get full text

Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients by Boxtel, Wim, Verhaegh, Gerald W., Engen‐van Grunsven, Ilse A., Strijp, Dianne, Kroeze, Leonie I., Ligtenberg, Marjolein J., Zon, Hans B., Hendriksen, Yara, Keizer, Diederick, Stolpe, Anja, Schalken, Jack A., Herpen, Carla M.

“…Androgen deprivation therapy (ADT) is first‐line palliative treatment in androgen receptor‐positive (AR+) salivary duct carcinoma (SDC), and response rates are…”
Get full text

Predicting whether patients in an acute medical unit are physiologically fit-for-discharge using machine learning: A proof-of-concept by Garssen, S.H., Vernooij, C.A., Kant, N., Koning, M.V., Bosch, F.H., Doggen, C.J.M., Veldkamp, B.P., Verhaegh, W.F.J., Oude Wesselink, S.F.

“…[Display omitted] •Predicting physiological discharge fitness in an Acute Medical Unit is feasible.•Using commonly available data from Electronic Medical…”
Get full text

A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol by Weijers, Jetty A M, Verhaegh, Gerald W, Lassche, G, van Engen-van Grunsven, Adriana C H, Driessen, Chantal M L, van Erp, Nielka P, Jonker, Marianne A, Schalken, Jack A, van Herpen, Carla M L

“…Salivary duct carcinoma (SDC) is a rare and aggressive subtype of salivary gland cancer, frequently associated with incurable recurrences and distant…”
Get full text

Noncoding RNAs as Novel Biomarkers in Prostate Cancer by Schalken, Jack A., Luna-Velez, M. V., Verhaegh, G. W., Rönnau, C. G. H.

“…Prostate cancer (PCa) is the second most common diagnosed malignant disease in men worldwide. Although serum PSA test dramatically improved the early diagnosis…”
Get full text

Complete sequence-based pathway analysis by differential on-chip DNA and RNA extraction from a single cell by van Strijp, D., Vulders, R. C. M., Larsen, N. A., Schira, J., Baerlocher, L., van Driel, M. A., Pødenphant, M., Hansen, T. S., Kristensen, A., Mir, K. U., Olesen, T., Verhaegh, W. F. J., Marie, R., van der Zaag, P. J.

“…We demonstrate on-chip, differential DNA and RNA extraction from a single cell using a microfluidic chip and a two-stage lysis protocol. This method enables…”
Get full text

DD3 : A new prostate-specific gene, highly overexpressed in prostate cancer by BUSSEMAKERS, M. J. G, VAN BOKHOVEN, A, VERHAEGH, G. W, SMIT, F. P, KARTHAUS, H. F. M, SCHALKEN, J. A, DEBRUYNE, F. M. J, NING RU, ISAACS, W. B

“…Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths in the Western male population. Despite the…”
Get full text

Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder by Luna‐Velez, Maria V., Dijkstra, Jelmer J., Heuschkel, Marina A., Smit, Frank P., van de Zande, Guillaume, Smeets, Dominique, Sedelaar, J. P. Michiel, Vermeulen, Michiel, Verhaegh, Gerald W., Schalken, Jack A.

“…Bladder urothelial cell carcinoma (UCC) incidence is about three times higher in men compared with women. There are several indications for the involvement of…”
Get full text

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment by Boerrigter, Emmy, Benoist, Guillemette E., Oort, Inge M., Verhaegh, Gerald W., Hooij, Onno, Groen, Levi, Smit, Frank, Oving, Irma M., Mol, Pieter, Smilde, Tineke J., Somford, Diederik M., Mehra, Niven, Schalken, Jack A., Erp, Nielka P.

“…Circulating RNAs extracted from liquid biopsies represent a promising source of cancer‐ and therapy‐related biomarkers. We screened whole blood from patients…”
Get full text

Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer by Hamid, Agus Rizal A H, Pfeiffer, Minja J, Verhaegh, Gerald W, Schaafsma, Ewout, Brandt, Andre, Sweep, Fred C G J, Sedelaar, John P M, Schalken, Jack A

“…Current endocrine treatment for advanced prostate cancer does not result in a complete ablation of adrenal androgens. Adrenal androgens can be metabolized by…”
Get full text

Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma by van Boxtel, W., Locati, L.D., van Engen-van Grunsven, A.C.H., Bergamini, C., Jonker, M.A., Fiets, E., Cavalieri, S., Tooten, S., Bos, E., Quattrone, P., Verhaegh, G.W., Schalken, J.A., Licitra, L., van Herpen, C.M.L.

“…Salivary duct carcinoma (SDC), an aggressive subtype of salivary gland cancer, is androgen receptor (AR)–positive in 67–96% of cases. In patients with locally…”
Get full text

LINC00857 expression predicts and mediates the response to platinum‐based chemotherapy in muscle‐invasive bladder cancer by Dudek, Aleksandra M., Kampen, Jasmijn G. M., Witjes, J. Alfred, Kiemeney, Lambertus A. L. M., Verhaegh, Gerald W.

“…Approximately 20% of patients with bladder cancer are diagnosed with muscle‐invasive disease (MIBC). The treatment involves radical cystectomy, but almost 50%…”
Get full text

The Identification of Small Molecule Inhibitors That Reduce Invasion and Metastasis of Aggressive Cancers by van de Merbel, Arjanneke F, van Hooij, Onno, van der Horst, Geertje, van Rijt-van de Westerlo, Cindy C M, van der Mark, Maaike H, Cheung, Henry, Kroon, Jan, Verhaegh, Gerald W, Tijhuis, Johan, Wellink, Antoine, Maas, Peter, Viëtor, Henk, Schalken, Jack A, van der Pluijm, Gabri

“…Transformed epithelial cells can activate programs of epithelial plasticity and switch from a sessile, epithelial phenotype to a motile, mesenchymal phenotype…”
Get full text

Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade by Lassche, Gerben, Tada, Yuichiro, van Herpen, Carla M. L., Jonker, Marianne A., Nagao, Toshitaka, Saotome, Takashi, Hirai, Hideaki, Saigusa, Natsuki, Takahashi, Hideaki, Ojiri, Hiroya, van Engen-Van Grunsven, Adriana C. H., Schalken, Jack A., Fushimi, Chihiro, Verhaegh, Gerald W.

“…Patients suffering from recurrent or metastatic (R/M) salivary duct carcinoma (SDC) are often treated with combined androgen blockade (CAB). However, CAB…”
Get full text

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer by Hamid, Agus Rizal A. H., Luna-Velez, Maria V., Dudek, Aleksandra M., Jansen, Cornelius F. J., Smit, Frank, Aalders, Tilly W., Verhaegh, Gerald W., Schaafsma, Ewout, Sedelaar, John P. M., Schalken, Jack A.

“…Castration-resistant prostate cancer (CRPC) is defined by resistance of the tumor to androgen deprivation therapy (ADT). Several molecular changes,…”
Get full text

The Androgen Regulated lncRNA NAALADL2-AS2 Promotes Tumor Cell Survival in Prostate Cancer by Groen, Levi, Yurevych, Viktor, Ramu, Harshitha, Chen, Johnny, Steenge, Lianne, Boer, Sabrina, Kuiper, Renske, Smit, Frank P, Verhaegh, Gerald W, Mehra, Niven, Schalken, Jack A

“…Castration resistance is the leading cause of death in men with prostate cancer. Recent studies indicate long noncoding RNAs (lncRNAs) to be important drivers…”
Get full text

The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice by Bijnsdorp, Irene V., van Royen, Martin E., Verhaegh, Gerald W., Martens-Uzunova, Elena S.

“…Prostate cancer (PCa) is the most common type of cancer and the second leading cause of cancer-related death in men. Despite extensive research, the molecular…”
Get full text